Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

ADDvise Group, Audiocast, Q2'25

By Inderes7/17/2025, 12:00 PM
ADDvise Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Staffan Torstensson
00:01 - 10:18

Thank you, operator, and good afternoon, everyone. Our performance in the second quarter was in line with our expectations across revenue, earnings, and it was a bit stronger when it comes to cash flow. We saw strong momentum in our lab equipment and clinical trials business, which helped offset the tough comparison to last year's Q2, when we benefited from several large clean room orders. While the macroeconomic environment remains uncertain with rising geopolitical tensions and new tariff developments, the market we operate in is holding up relatively well. That said, we are seeing some softness in large CapEx related sales cycles. We are also experiencing a headwind from the recent strengthening of the SEK, which has impacted our top line and earnings through translation effects. Looking ahead, our focus remains clear: to continue pushing our acquisition strategy and to deliver sustainable value creation for our shareholders. With that, let's take a closer look at our Q2 numbers. Our net sales came in at 396 million SEK, which resulted in a year-over-year growth of 4%. Adjusted for FX and excluding FX, EBITDA came in at 61 million SEK, in line with last year's 62, which takes us to a margin of 16%, slightly stronger than last year's 15. Looking at the cash flow from operations, it came in strong at 70 million compared to -19 last year. During June, we finalized our new financing structure. We have now added proper bank financing combined with bond financing at better terms. If we apply the new financing structure for this quarter, our proforma net profit will be more than double what is reported. The proforma figure will be 2023 million SEK, and when compared to the reported 10.8 million, net leverage came in at three times. Taking a closer look at our new financing structure. Sure, gross debt was reduced by approximately 480 million SEK. Our old SEK and US bonds were partly refinanced with a new SEK bond of 800 million, with a margin of 350 basis points over Stibor, and a new bank facility with a total of 450 million SEK. With a term loan of 15 million USD and an RCF of 300 million SEK. All in all, we have reduced our annual financing costs by approximately 56 million SEK. Two-thirds comes from lower gross debt, and one-third from better terms. Uh, meaning lower interest margins. The capitalized transaction costs going forward will be about 6 million SEK a year, which is 15 million SEK less than the previous structure. This will only affect the net profit. I mean, no cash flow effect. Coming into the commercial and operational highlights of Q2, we observed stable business momentum in both healthcare and lab sectors during the quarter. We continue to focus on efficiency initiatives to ensure that we are maximizing our potential to create shareholder value. Managing working capital is one of our top priorities. During the quarter, we saw cash flow increase compared to the same quarter last year. Approximately 42% of our sales in the quarter came from Europe. And, uh. Second largest market in North America. And the third is South America. Looking at our sales by product category, the top three for the year are laboratory equipment. Uh, 41%, followed by medical consumables at 33%, and medical equipment at 21%. High activity in laboratory equipment and also in clinical trials in the US. On the topic of tariffs, the direct impact at, I mean, level one, referring to products manufactured outside the US and imported for sales into the US, is relatively limited. We have stated before, and it's the same at this stage. It's 30 to 40 million SEK. Most of our US-based companies both manufacture and sell their products domestically within the US market. That said, we do rely on certain components sourced internationally for our US production. The positive aspect is that our products are essential in nature, designed to extend, improve, or even save lives, which provides a certain degree of resilience regardless of broader trade dynamics or geographical tensions. Splitting ADDvise Group into healthcare and lab segments and focusing on healthcare. Our sales came in at 235 million for the quarter, showing an organic growth of 1% FX adjusted and -8% non-adjusted. Looking at the first six months, we saw an organic growth of 1% and 6% FX adjusted. The lab segment reported sales of 161 million for the quarter. Organic sales came in at 3% and 8% FX adjusted. Looking at profit margins, healthcare came in at a 15% EBITDA margin and lab came in at 21%. Lab delivered a strong margin. And I would say healthcare came in at a stable level. Looking at net sales by geography for the healthcare segment, North America continued to be the key market, with roughly 51% of sales. And we don't see any big changes going forward. Having said that, Europe has shown good development in the lab segment. Europe is the largest market, followed by the US. We remain focused on profitable growth, stable returns, and maintaining a well-balanced debt level, all underpinned by the execution of our acquisition strategy. A strong emphasis is placed on EBITDA growth and return on capital employed as our key financial performance indicators. EBITDA growth will be driven by a combination of organic expansions and strategic acquisitions. Our long-term target is to double EBITDA every five years. A dividend remains part of our long-term financial framework, but distribution will be considered once all other long-term financial goals are at satisfactory levels. Goals are at satisfactory levels. We are committed to maintaining a maximum net debt level to EBITDA ratio of three times. While a dividend remains a part, uh. I mean, the dividend will come into play when all the others of our long-term financial goals are met at a sustainable and appropriate level. I'm now handing over to Johan to take you through the group's financial performance. Thank you, Staffan, and good afternoon, everyone. I'm happy to be here today and take you through the numbers for the second quarter of 2025.

Johan Irwe
10:18 - 14:50

Here today and take you through the numbers for the second quarter of 2025. EBITDA, which is ADDvise's main key metric for measuring profit, gives a fair view of the financial performance of our companies. EBITDA is defined as operating profit before amortization, impairment expenses, and revaluation related to acquisitions, as well as non-recurring items. EBITDA is our key metric from this year, and figures in this graph have been historically adjusted for the new definition. EBITDA in the second quarter amounted to 61 million, which corresponds to a margin of 16%. Uh, both EBITDA and EBITDA margin are in line with the same quarter last year, as we have pointed out in earlier quarterly reports. Uh, 2024 faced tough comparables from 2023. However, the individual quarters of 2024 should be considered a normal level of profits. Uh, which means that from Q4, we are now on a normalized level of sales and profitability on a rolling 12-month basis, which is confirmed by this quarter as well. And for the last 12 months, EBITDA amounts to 267 million, which corresponds to a margin of 16%. Moving on to cash flow and capital efficiency. Uh, on this slide, when we talk about cash generation, we look at the underlying cash flow generated by our companies, with deductions from changes in working capital as well as depreciation and investments in our asset base, including lease payments. And in the second quarter, we see a moderate working capital build of 4.8 million. And working capital efficiency and optimization is and will always be a key focus area for us and our companies. Depreciations include depreciation on fixed assets as well as depreciation on right-of-use assets related to leases, and the net between depreciation, leases, and investments is 2 million, indicating higher new investments than the depreciation on existing assets, mainly driven by production efficiency and investments in our South American business. Total cash generation from operations in the quarter was 54 million, relative to an EBITDA of 61 million. We consider this a solid level of cash generation in the quarter. Return on Capital Employed (ROCE), which measures profitability and how efficiently we use our capital, was 12% in the quarter. And from this year, this metric is one of ADDvise long-term financial targets with a long-term goal of a 15% return on capital employed. Moving over to the financial position. Uh, here, our long-term net leverage target is three times net debt over EBITDA. And in the quarter, net leverage was 3.0 times EBITDA. And the issue. The right issue was finalized in April and added 457 million before transaction costs to the company. It also included a warrant that could potentially add an additional 172 million in Q1 2026 if fully exercised. As Staffan mentioned earlier, the new capital structure with bank financing and bonds at better terms will reduce our yearly interest expenses by around 56 million SEK compared to the old financing structure. Available liquidity is good. Cash at the end of the quarter was 140 million, with an additional 111 million available in unused credit facilities. And that was all from me. I will now hand over to Staffan for some closing remarks.

Staffan Torstensson
14:53 - 16:05

Thank you, Johan. I will summarize and give you our takeaways from Q2 before we open up for questions. Organic sales decreased by 4%, but if we adjust for FX, it increased by 4% for the quarter. Uh, EBITA on a stable level despite the FX headwind. Production and operational expenses are in the same currency as revenue. So, this has a good effect for us. Um, cash flow, uh, solid cash generation, new financing is done. Uh, bond refinancing at better terms and bank facility. All in all, better flexibility and lower financial costs. On the acquisition side, we continue to work on a couple of interesting opportunities. Uh, as said before, it has to be right. Uh, we are not stressed, uh, meaning that we look for, uh, very good quality, uh, at, uh, a reasonable price tag. With that said, we open up for questions.

Operator
16:08 - 16:29

You wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Philip Ekengren from ABG. Go ahead and ask your question. Please go ahead.

Philip Ekengren
16:30 - 16:43

It also included a warrant that could potentially add an additional 172 million in Q1 2026 if fully exercised. Operator. And good afternoon, everyone. Uh, so first off, just a quick clarification on the direct impact from tariffs. I know it's limited, but you said 30 to 40 million. Is that an annual number? Is that correct?

Staffan Torstensson
16:43 - 16:44

Yes.

Philip Ekengren
16:45 - 16:47

Yep. Perfect. Good. Uh, okay. So.

Staffan Torstensson
16:48 - 16:54

But let's make sure that this is, I mean, that's level one, right? And I also stress.

Philip Ekengren
16:54 - 16:54

That.

Staffan Torstensson
16:54 - 16:56

There is another level. Yeah. Okay, good.

Philip Ekengren
16:57 - 17:16

Sure. Good. Uh, let's look at the sales growth, because both segments seem to deliver organic growth and are kind of in line with expectations if we look past the currency effects. But could you please give some more detail on that. Are there any particular companies or sub-segments that are performing well or worse? Uh, if that's the case?

Staffan Torstensson
17:18 - 17:43

No. But as I said, laboratory equipment did very well. Uh, clinical trials in the US were also performing very well during the quarter. And, uh, I would say that the remaining is, uh, delivering at a stable level. So, I mean, there is no real surprise on the downside.

Philip Ekengren
17:45 - 18:02

Uh, that's good to hear. And how would you describe the visibility? Could we expect continued growth, or should we see a slowdown in the near term? I mean, you talk about some larger CapEx projects being a bit suspended or at least more hesitant. But could you say anything about the visibility, please?

Staffan Torstensson
18:04 - 18:36

I mean, it's of course very difficult to look into the future, but I mean, looking at our orders, and if we then adjust for effects and also adjust for our big clean room orders that we had last year. I mean, we are more or less, flat to a bit positive. So, I mean, that's a good indication that we are still growing and we are set for growth.

Philip Ekengren
18:38 - 19:02

Sounds good. Sounds reasonable. Um, the lab margin surprised me somewhat. I know it can be volatile, but what can you say about it? Because you say, 'lab?' Lab also surprised you a bit. I got that impression at least. But what can you say here? What do you think about the margins for the rest of the year in terms of volatility and a kind of normalized level? What do you think is reasonable here?

Staffan Torstensson
19:02 - 19:32

From quarter to quarter? Of course, it's difficult to predict, and it can be volatile. Uh, but I will say that the lab is performing where they should perform. So, uh, but even having said that, I mean, we are pushing for even higher margins. But, as you also know, there is a bit of project-related business in the lab which can disturb the picture a bit.

Philip Ekengren
19:35 - 19:59

I mean, we are more or less, uh, flat to a bit positive. And then finally, I was reading the prospectus from the 11th of July. Now, from the bond prospectus. Uh, and it states, and I'll quote here that you're involved in a dispute regarding an earn-out claim amounting to approximately €6 million. Could you provide any insights on its current state? What is that about and what should we think about going forward?

Staffan Torstensson
20:00 - 21:09

Uh, it relates to, if you recall, we had this big clinical trials Europe, which had one order with a contract that was terminated. It was supposed to run for three years, but it got terminated in year one because the client was not able to recruit a sufficient number of patients. So what happened there is that we received all cash from all sales on that contract in one year. Uh, and that, of course, affected the performance of that company. So I guess that's related to that, and we are in talks with them. But we have a clear and different view in terms of how we should deal with that when it comes to earnout calculation.

Philip Ekengren
21:11 - 21:14

I mean, we are more or less, uh, flat to a bit positive. Thanks for the clarification. That's all for me for now. Thanks.

Johan Irwe
21:15 - 21:15

Thank you.

Operator
21:20 - 21:34

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
21:38 - 21:52

Thank you and good afternoon, and thank you for taking my questions. Um, my first question is regarding the market hesitation concerning larger CapEx investments. Uh, do you see this affecting both healthcare and lab?

Staffan Torstensson
21:53 - 22:16

I would say it's mostly lab, and that may be a bit contradictory because the lab was performing, uh, well. I mean, in terms of laboratory equipment, uh, so I'm not saying that it takes longer time. Uh, that's my feeling.

Christian Lee
22:20 - 22:44

Okay. Thank you. And, uh, the EBITA margin on a rolling 12 months basis was 16%, which aligns with the level of 2024. Uh, is this the normalized level we should expect going forward, or do you see any headroom for improvements? Uh, given your, uh, comment about the lab being at a healthy level and the healthcare being at a stable margin level,

Staffan Torstensson
22:45 - 23:37

Christian, we are always pushing for higher margins. So, I mean, we are not satisfied at all, but we see that, of course, there is, as you can observe from quarter to quarter, a 1 or 2 percent change, but it's extremely difficult to outline if it's a stable level or where it is. But, I mean, it's clear that the companies are now operating well, and we can continue to make them even better, which then will result in even higher margins. I mean, we have a clear target that we would lift the margins to about 20%.

Christian Lee
23:40 - 23:57

All right. Uh, thank you. Uh, and given that EBIT, EBITDA for the first half of the year, uh, is down 3% year over year. Uh, do you still expect to reach your new target of increasing EBITDA by 15% this year?

Staffan Torstensson
23:59 - 24:17

But that will mean we need to do a proforma and need to do an acquisition. I mean, standalone, where we are now, it will be tough. And as we have said before, I mean, the 15% growth must be helped by acquisitions.

Christian Lee
24:21 - 24:43

Right. And you also commented that you saw good acquisition opportunities at attractive valuations. But given that your net debt leverage is at three times as of Q2, do you expect to continue your consolidation strategies this year, or will you focus on decreasing the debt ratio first?

Staffan Torstensson
24:46 - 25:24

I mean, hopefully, we will succeed in doing both, even though it's a tough thing, but we will continue. And we're looking into acquisitions. You never know when you can actually close the acquisitions. So, we are working with a couple of opportunities as we speak. So, uh, we have clear ambitions to, uh, do acquisitions. Uh, having said that, of course, we need to have a healthy debt level going forward.

Christian Lee
25:27 - 25:30

And you also commented that you saw good acquisition opportunities at attractive valuations. That's very clear. Thank you very much. That's all from me.

Staffan Torstensson
25:31 - 25:31

Thank you.

Operator
25:36 - 25:42

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Staffan Torstensson
25:46 - 25:53

Thank you all. Uh, and have a continuously good day. And a good summer.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…